Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities

Figure 1 Scores (Fibrosis-4, FibroScan-AST, Agile 3+, Agile 4) and values (Liver stiffness measurement, Mac2-binding protein glycosylation isomer) of patients with hepatocellular carcinoma (n = 17), esophagogastric varices (n = 16), and both hepatocellular carcinoma and esophagogastric varices (n = 9). ^aP < 0.05, ^bP < 0.01. HCC: Hepatocellular carcinoma; EGV: Esophagogastric varices; LSM: Liver stiffness measurement; FAST: FibroScan-AST; M2BPGi: Mac2-binding protein glycosylation isomer.

Figure 2 Flow chart. A: A flowchart in sorting nonalcoholic fatty liver disease (NAFLD) patients using the fibrosis-4 index, Agiles, and other fibrosis markers; B: A proposal algorithm to narrow the high-risk group of NAFLD patients with hepatocellular carcinoma and/or esophagogastric varices. HCC: Hepatocellular carcinoma; EGV: Esophagogastric varices; LSM: Liver stiffness measurement; M2BPGi: Mac2-binding protein glycosylation isomer; NAFLD: Nonalcoholic fatty liver disease.